+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

In-Silico Drug Discovery Market by Technology Platform, Application, End User, Deployment Model, Therapeutic Area - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925152
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The In-Silico Drug Discovery Market grew from USD 2.86 billion in 2024 to USD 3.13 billion in 2025. It is expected to continue growing at a CAGR of 9.12%, reaching USD 4.83 billion by 2030.

Pioneering Advances Define In-Silico Drug Discovery Today

The convergence of computational power and advanced algorithms has catalyzed a paradigm shift in drug discovery, ushering in an era where in-silico methods are integral to the early stages of pharmaceutical development. This transformation began with isolated computational chemistry experiments but has accelerated into fully integrated workflows that incorporate bioinformatics, structural modeling, and machine learning. The ability to simulate molecular interactions, predict absorption-distribution-metabolism-excretion-toxicity (ADMET) profiles, and optimize lead compounds digitally has reduced the time and cost barriers that once constrained traditional bench-based research.

Over the past decade, collaborations between academic institutions, biotechnology firms, and contract research organizations have blurred the lines between theoretical modeling and experimental validation. High performance computing clusters now run complex algorithms that were once the exclusive domain of supercomputers, while cloud-driven simulations democratize access to these capabilities. As a result, virtual screening campaigns that once took months to complete can now be executed in days, allowing scientists to explore larger chemical spaces more efficiently.

This report provides an in-depth executive overview of these developments, highlighting transformative shifts, regulatory and economic influences, segmentation insights, regional dynamics, and key players shaping the market. By understanding the current landscape, stakeholders can make informed strategic decisions, allocate resources effectively, and anticipate emerging opportunities within the dynamic field of in-silico drug discovery.

Rapid Technological Convergence Reshapes Discovery Landscape

The landscape of in-silico drug discovery has evolved from standalone computational tasks to a cohesive ecosystem driven by interdisciplinary collaboration. Innovations in high performance computing have unlocked the capacity to process petabyte-scale datasets, empowering teams to tackle complex biomolecular interactions with unprecedented resolution. Concurrently, breakthroughs in machine learning and AI have enabled predictive models that refine candidate selection throughout the discovery pipeline, from target validation to lead optimization.

As computational chemistry merges with sophisticated bioinformatics tools, researchers now harness integrated platforms that generate actionable insights at each stage. Molecular modeling software produces three-dimensional simulations of protein-ligand interactions, while AI-driven analytics reveal hidden structure-activity relationships. This convergence has elevated virtual screening from a preliminary filtering tool to a cornerstone of drug development strategy.

In parallel, the rise of cloud-based deployment models has accelerated adoption across academic and commercial research environments. Organizations of varied scale no longer face prohibitive infrastructure costs, enabling agile experimentation and rapid iteration. As these technological trends coalesce, the in-silico drug discovery landscape stands poised for continued expansion, driving faster, more cost-effective pathways to novel therapeutics.

Navigating the Ripple Effects of 2025 US Pharmaceutical Tariffs

The introduction of new tariffs on pharmaceutical imports and export-related services in 2025 has created ripples throughout the global in-silico drug discovery market. Increased duties on hardware components critical for high performance computing have driven procurement costs upward, prompting organizations to reevaluate capital expenditure plans. This shift has particularly affected on-premise deployments where upfront investments in servers and workstations have become more expensive due to import levies.

Simultaneously, licensing fees for proprietary software tied to international export regulations have experienced marginal increases, impacting budgets for computational chemistry, molecular modeling, and AI-driven analytics suites. Some vendors have responded by offering subscription-based models with flexible payment terms, while others are expanding local support infrastructures to mitigate tariff burdens and streamline compliance.

Despite these challenges, the market has demonstrated resilience as stakeholders pivot toward cloud-based solutions. By leveraging geographically distributed data centers unaffected by certain tariff classifications, research organizations can maintain access to cutting-edge computational resources without incurring high import costs. This strategic rebalancing underscores the market’s adaptability and its capacity to absorb economic headwinds while sustaining growth trajectories.

Deconstructing Market Segments to Illuminate Growth Vectors

A nuanced examination of market segments reveals distinct drivers across technology platforms, applications, end users, deployment models, and therapeutic focus areas. Computational chemistry and bioinformatics providers lead with foundational tools for structure elucidation, while high performance computing offers the raw processing power necessary to run large-scale simulations. Machine learning and AI vendors differentiate themselves by delivering predictive analytics that streamline decision-making, and molecular modeling developers continuously refine visualization and docking algorithms to enhance accuracy.

When assessing application domains, ADMET prediction emerges as a cornerstone, subdivided into modules for predicting absorption, distribution, excretion, metabolism, and toxicity profiles. Lead identification and optimization spans de novo design frameworks alongside fragment-based optimization approaches, enabling teams to engineer novel candidates with improved properties. Virtual screening platforms integrate ligand-based methods that exploit chemical similarity and structure-based workflows that leverage three-dimensional protein conformations. Pharmacokinetics modeling provides dynamic insights into drug behavior in vivo, while target identification and validation tools accelerate the early stages of hypothesis generation.

End users demonstrate varied adoption trends: academic and research institutes prioritize open architectures and extensibility, contract research organizations focus on turnkey solutions that support client projects, and pharmaceutical and biotechnology companies invest heavily in integrated platforms to enhance internal discovery pipelines. Deployment choices bifurcate into cloud-based offerings that emphasize scalability and collaboration, and on-premise models that deliver maximal control over data security. Therapeutic area segmentation highlights significant activity in cardiovascular research, central nervous system disorders, infectious diseases, and oncology, reflecting both market need and the modular adaptability of in-silico methodologies.

Regional Market Dynamics Offer Strategic Opportunity Windows

Regional dynamics underscore the interplay between scientific infrastructure, regulatory frameworks, and funding ecosystems. In the Americas, robust academic networks and venture capital availability have fostered rapid innovation, with leading technology hubs driving adoption of both open-source and commercial platforms. Regulatory agencies within these markets emphasize data integrity and validation standards, ensuring that in-silico results complement traditional experimental findings with rigorous quality controls.

Across Europe, Middle East & Africa, a diverse tapestry of research priorities shapes market behavior. Established biotech clusters in Western Europe coexist with emerging centers of excellence in the Middle East, each navigating complex regulatory landscapes. Collaborative initiatives and public-private partnerships have catalyzed technology transfer, while funding mechanisms from supranational bodies have accelerated cross-border projects focused on infectious disease and oncology applications.

The Asia-Pacific region exhibits surging demand driven by governmental investment in biotechnology infrastructure and a growing pipeline of local pharmaceutical innovators. Cloud-based deployment models have gained particular traction here, enabling geographically dispersed research teams to access high performance computing without substantial capital outlay. Regulatory bodies are increasingly adopting guidelines that recognize computational data as a complement to in vitro and in vivo studies, further solidifying the region’s position as a key growth engine.

Leading Innovators Driving Next-Gen Computational Platforms

Market leadership is shaped by companies that blend scientific expertise with robust computing architectures. Several established vendors have expanded their portfolios to encompass end-to-end workflows, integrating molecular modeling, ADMET prediction, and virtual screening into unified platforms. These incumbents leverage decades of domain knowledge to refine algorithmic accuracy and build large curated databases that enhance predictive capabilities.

Emerging players differentiate through niche innovations in machine learning algorithms and cloud-native architectures. By introducing automated model training, adaptive learning pipelines, and seamless API integrations, these startups accelerate project timelines and reduce the need for manual intervention. Strategic partnerships between software developers and hardware manufacturers have yielded optimized solutions that capitalize on graphics processing units and specialized accelerators for quantum-inspired computing.

Contract research organizations and academic spin-offs also contribute significantly to the competitive landscape. Their collaborations with industrial partners facilitate the co-development of bespoke tools, while tailored service offerings ensure that specialized knowledge can be rapidly deployed across diverse therapeutic areas. This confluence of established platforms and agile newcomers drives continuous evolution in the in-silico drug discovery ecosystem.

Strategic Imperatives for Accelerating In-Silico Adoption

Industry leaders should prioritize investments in integrated platforms that combine high performance computing with advanced AI-driven modules. By fostering collaborations with academic institutions and contract research organizations, they can accelerate the development of proprietary algorithms and expand access to curated data sets. Emphasizing interoperability and open APIs will enable seamless integration with existing laboratory information management systems, reducing silos and promoting cross-disciplinary workflows.

Leaders must also refine their commercialization strategies by offering flexible licensing options. Subscription-based and consumption-driven models empower clients to scale resources according to project demands, while reducing upfront capital commitments. Additionally, expanding regional support networks and localized compliance frameworks can mitigate the impact of evolving tariff regimes and regulatory requirements.

Finally, committing to ongoing validation studies and transparent benchmarking will enhance user trust and drive broader adoption. By publishing performance metrics in peer-reviewed journals and industry forums, companies can demonstrate the real-world impact of in-silico approaches, fostering a data-driven culture that bridges computational predictions and experimental outcomes.

Robust Methodology Underpinning Market Intelligence Findings

The research methodology underpinning this report combines primary and secondary data collection with rigorous qualitative and quantitative analyses. Expert interviews with senior executives, scientific directors, and computational chemists provided firsthand insights into technology adoption patterns, buying criteria, and pain points. These conversations were supplemented by an extensive review of peer-reviewed literature, patent filings, annual reports, and press releases to ensure a comprehensive understanding of current trends.

Secondary research involved analyzing databases of published research projects, clinical trial registries, and government funding allocations to identify growth corridors and investment hotspots. Market metrics were validated through triangulation, cross-referencing data from multiple independent sources. Key performance indicators, such as algorithm accuracy improvements, throughput enhancements, and cost per simulation, were tracked over time to quantify progress within each segment.

A structured framework was employed to segment the market across technology platforms, application domains, deployment models, therapeutic areas, and end users. Each segment underwent a detailed SWOT analysis to assess strengths, weaknesses, opportunities, and threats. This multi-layered approach ensured that findings are robust, actionable, and aligned with the strategic objectives of decision-makers in both commercial and academic settings.

Converging Insights Chart the Future of Digital Drug Discovery

The insights presented converge to paint a cohesive picture of an industry at the forefront of innovation. Technological advancements in computing power, machine learning, and molecular modeling are driving unprecedented efficiency gains, while regulatory and economic challenges underscore the importance of strategic flexibility. Segment-level analysis highlights where investments are yielding the greatest returns, from ADMET prediction modules to virtual screening frameworks.

Regional variations reveal distinct opportunity landscapes, with each geography offering unique advantages in terms of infrastructure, funding, and regulatory acceptance of computational methods. Key players-ranging from established incumbents to pioneering startups-are shaping market dynamics through complementary strengths in platform integration and algorithmic innovation.

As in-silico methodologies become more deeply embedded in drug discovery pipelines, the industry is poised to unlock faster candidate identification, improved safety profiles, and reduced development timelines. Stakeholders equipped with these comprehensive insights can position their organizations to capitalize on emerging trends, mitigate risks, and drive sustained growth in this dynamic field of computational therapeutics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology Platform
    • Computational Chemistry And Bioinformatics
    • High Performance Computing
    • Machine Learning And Ai
    • Molecular Modeling
  • Application
    • Admet Prediction
      • Absorption Prediction
      • Distribution Prediction
      • Excretion Prediction
      • Metabolism Prediction
      • Toxicity Prediction
    • Lead Identification And Optimization
      • De Novo Design
      • Fragment Based Optimization
    • Pharmacokinetics Modeling
    • Target Identification And Validation
    • Virtual Screening
      • Ligand Based Virtual Screening
      • Structure Based Virtual Screening
  • End User
    • Academic And Research Institutes
    • Contract Research Organizations
    • Pharmaceutical And Biotechnology Companies
  • Deployment Model
    • Cloud Based
    • On Premise
  • Therapeutic Area
    • Cardiovascular
    • Central Nervous System
    • Infectious Diseases
    • Oncology
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Dassault Systèmes SE
  • Certara, Inc.
  • Schrödinger, Inc.
  • Simulations Plus, Inc.
  • OpenEye Scientific Software, Inc.
  • Exscientia plc
  • Atomwise, Inc.
  • Insilico Medicine, Inc.
  • Cresset BioMolecular Discovery Ltd
  • Chemical Computing Group ULC

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. in-Silico Drug Discovery Market, by Technology Platform
8.1. Introduction
8.2. Computational Chemistry and Bioinformatics
8.3. High Performance Computing
8.4. Machine Learning and Ai
8.5. Molecular Modeling
9. in-Silico Drug Discovery Market, by Application
9.1. Introduction
9.2. Admet Prediction
9.2.1. Absorption Prediction
9.2.2. Distribution Prediction
9.2.3. Excretion Prediction
9.2.4. Metabolism Prediction
9.2.5. Toxicity Prediction
9.3. Lead Identification and Optimization
9.3.1. De Novo Design
9.3.2. Fragment Based Optimization
9.4. Pharmacokinetics Modeling
9.5. Target Identification and Validation
9.6. Virtual Screening
9.6.1. Ligand Based Virtual Screening
9.6.2. Structure Based Virtual Screening
10. in-Silico Drug Discovery Market, by End User
10.1. Introduction
10.2. Academic and Research Institutes
10.3. Contract Research Organizations
10.4. Pharmaceutical and Biotechnology Companies
11. in-Silico Drug Discovery Market, by Deployment Model
11.1. Introduction
11.2. Cloud Based
11.3. on Premise
12. in-Silico Drug Discovery Market, by Therapeutic Area
12.1. Introduction
12.2. Cardiovascular
12.3. Central Nervous System
12.4. Infectious Diseases
12.5. Oncology
13. Americas in-Silico Drug Discovery Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa in-Silico Drug Discovery Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific in-Silico Drug Discovery Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Dassault Systèmes SE
16.3.2. Certara, Inc.
16.3.3. Schrödinger, Inc.
16.3.4. Simulations Plus, Inc.
16.3.5. OpenEye Scientific Software, Inc.
16.3.6. Exscientia plc
16.3.7. Atomwise, Inc.
16.3.8. Insilico Medicine, Inc.
16.3.9. Cresset BioMolecular Discovery Ltd
16.3.10. Chemical Computing Group ULC
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IN-SILICO DRUG DISCOVERY MARKET MULTI-CURRENCY
FIGURE 2. IN-SILICO DRUG DISCOVERY MARKET MULTI-LANGUAGE
FIGURE 3. IN-SILICO DRUG DISCOVERY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IN-SILICO DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IN-SILICO DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IN-SILICO DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COMPUTATIONAL CHEMISTRY AND BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY HIGH PERFORMANCE COMPUTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MACHINE LEARNING AND AI, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ABSORPTION PREDICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DISTRIBUTION PREDICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY EXCRETION PREDICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY FRAGMENT BASED OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACOKINETICS MODELING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION AND VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED VIRTUAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED VIRTUAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 60. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 62. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 63. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 64. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 66. CANADA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 67. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 68. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 72. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 74. MEXICO IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 108. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 109. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 111. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 112. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 113. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 115. GERMANY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 116. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 117. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 120. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 121. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 123. FRANCE IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 132. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 133. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 135. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 136. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 137. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 139. ITALY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 140. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 141. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 143. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 144. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 145. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 147. SPAIN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 172. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 173. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 175. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 176. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 177. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 179. DENMARK IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 188. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 189. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 191. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 193. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 195. QATAR IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 196. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 197. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 199. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 200. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 201. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 203. FINLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 220. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 221. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 223. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 224. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 225. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 227. EGYPT IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 228. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 229. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 231. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 232. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 233. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 235. TURKEY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 244. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 245. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 247. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 248. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 249. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 251. NORWAY IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 252. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 253. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 255. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 256. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 257. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 259. POLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC IN-SILICO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 277. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 278. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 280. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 281. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 282. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 284. CHINA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 285. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 286. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 288. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 289. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 290. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 292. INDIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 293. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 294. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 295. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 297. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 298. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 300. JAPAN IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY LEAD IDENTIFICATION AND OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA IN-SILICO DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KORE

Companies Mentioned

The companies profiled in this In-Silico Drug Discovery market report include:
  • Dassault Systèmes SE
  • Certara, Inc.
  • Schrödinger, Inc.
  • Simulations Plus, Inc.
  • OpenEye Scientific Software, Inc.
  • Exscientia plc
  • Atomwise, Inc.
  • Insilico Medicine, Inc.
  • Cresset BioMolecular Discovery Ltd
  • Chemical Computing Group ULC

Methodology

Loading
LOADING...

Table Information